Studying livmoniplimab plus budigalimab for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two investigational drugs given through a vein to see how they work in Chinese adults with advanced liver cancer that has already been treated with one immunotherapy. The goal is to find out if this new two-drug combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced liver cancer (HCC) that cannot be fully removed with surgery or has spread beyond the liver.
- Your liver function should be fairly good (classified as Child-Pugh A).
- You must have already received one type of immunotherapy (a checkpoint inhibitor) as your first treatment for this cancer.
- You should be in relatively good physical health (able to do most daily activities) with an ECOG score of 0 or 1.
- You cannot have active, untreated brain tumors from the cancer, or a history of certain autoimmune diseases like lupus or rheumatoid arthritis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of two drugs (sintilimab, an immunotherapy, and lenvatinib, a targeted therapy) followed by local treatments to try to cure advanced liver cancer that has spread to a few other parts of the body. The goal is to shrink the cancer enough that surgery or radiation can remove it completely.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This Phase 2/3 study tests whether combining rulonilimab with lenvatinib can control unresectable advanced liver cancer (HCC) that cannot be removed by surgery or treated locally. You may be considered if you have not had prior whole-body (systemic) cancer treatments and your organs and blood counts are strong enough.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.